These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2632268)

  • 21. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
    Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
    Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
    Gerrits CJ; Creemers GJ; Schellens JH; Wissel P; Planting AS; Kunka R; Selinger K; de Boer-Dennert M; Marijnen Y; Harteveld M; Verweij J
    Br J Cancer; 1996 Mar; 73(6):744-50. PubMed ID: 8611374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
    McLeod HL; Cassidy J; Powrie RH; Priest DG; Zorbas MA; Synold TW; Shibata S; Spicer D; Bissett D; Pithavala YK; Collier MA; Paradiso LJ; Roberts JD
    Clin Cancer Res; 2000 Jul; 6(7):2677-84. PubMed ID: 10914709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
    Delaunoit T; Burch PA; Reid JM; Camoriano JK; Kobayash T; Braich TA; Kaur JS; Rubin J; Erlichman C
    Invest New Drugs; 2006 Jul; 24(4):327-33. PubMed ID: 16502355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial clinical studies of piritrexim.
    Laszlo J; Brenckman WD; Morgan E; Clendeninn NJ; Williams T; Currie V; Young C
    NCI Monogr; 1987; (5):121-5. PubMed ID: 3323908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
    Bleehen NM; Newman HV; Rampling RP; Ramsay JR; Roberts JT; Bedford P; Nethersell AB
    Br J Cancer; 1995 Sep; 72(3):766-8. PubMed ID: 7669591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
    Sausville EA; Arbuck SG; Messmann R; Headlee D; Bauer KS; Lush RM; Murgo A; Figg WD; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz AM
    J Clin Oncol; 2001 Apr; 19(8):2319-33. PubMed ID: 11304786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.
    Stuart NS; Crawford SM; Blackledge GR; Newlands ES; Slack J; Hoffman R; Stevens MF
    Cancer Chemother Pharmacol; 1989; 23(5):308-10. PubMed ID: 2706736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
    Panasci L; Stinson SF; Melnychuk D; Sandor V; Miller WH; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
    J Clin Oncol; 2003 Jan; 21(2):232-40. PubMed ID: 12525514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
    Awada A; Thödtmann R; Piccart MJ; Wanders J; Schrijvers AH; Von Broen IM; Hanauske AR;
    Eur J Cancer; 2003 Apr; 39(6):742-7. PubMed ID: 12651198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.